Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Improving 3-Hour Sepsis Bundled Care Outcomes: Implementation of a Nurse-Driven Sepsis Protocol in the Emergency Department.

Moore WR, Vermuelen A, Taylor R, Kihara D, Wahome E.

J Emerg Nurs. 2019 Nov;45(6):690-698. doi: 10.1016/j.jen.2019.05.005. Epub 2019 Jun 22.

PMID:
31235077
2.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

3.

Examining the Frequency of Stimulant Misuse among Patients with Primary Disorders of Hypersomnolence: A Retrospective Cohort Study.

Mantyh WG, Auger RR, Morgenthaler TI, Silber MH, Moore WR.

J Clin Sleep Med. 2016 May 15;12(5):659-62. doi: 10.5664/jcsm.5788.

4.

VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.

Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Long L, Ghannoum MA.

Antimicrob Agents Chemother. 2015 Apr;59(4):1992-7. doi: 10.1128/AAC.04902-14. Epub 2015 Jan 20.

5.

Improving sleep: outcomes from a worksite healthy sleep program.

Steffen MW, Hazelton AC, Moore WR, Jenkins SM, Clark MM, Hagen PT.

J Occup Environ Med. 2015 Jan;57(1):1-5. doi: 10.1097/JOM.0000000000000370.

PMID:
25563534
6.

The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.

Warrilow AG, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL.

Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7. doi: 10.1128/AAC.03707-14. Epub 2014 Sep 15.

7.

Design and optimization of highly-selective fungal CYP51 inhibitors.

Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3455-8. doi: 10.1016/j.bmcl.2014.05.068. Epub 2014 Jun 9.

PMID:
24948565
8.

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.

Rafferty SW, Eisner JR, Moore WR, Schotzinger RJ, Hoekstra WJ.

Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7. doi: 10.1016/j.bmcl.2014.04.024. Epub 2014 Apr 16.

PMID:
24775307
9.

Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.

Shetty RS, Lee Y, Liu B, Husain A, Joseph RW, Lu Y, Nelson D, Mihelcic J, Chao W, Moffett KK, Schumacher A, Flubacher D, Stojanovic A, Bukhtiyarova M, Williams K, Lee KJ, Ochman AR, Saporito MS, Moore WR, Flynn GA, Dorsey BD, Springman EB, Fujimoto T, Kelly MJ.

J Med Chem. 2011 Jan 13;54(1):179-200. doi: 10.1021/jm100659v. Epub 2010 Dec 2.

PMID:
21126027
10.

Recommendations for optimization of fortified and blended food aid products from the United States.

Fleige LE, Moore WR, Garlick PJ, Murphy SP, Turner EH, Dunn ML, van Lengerich B, Orthoefer FT, Schaefer SE.

Nutr Rev. 2010 May;68(5):290-315. doi: 10.1111/j.1753-4887.2010.00288.x. Review.

PMID:
20500790
11.

Assessing analytical variability of measurement of vitamin A in corn-soy blend.

Moore WR, DeVries J, MacDonald J, Hare L, Carson J, Chaudhari P, DeVries J, Fontana J, Golz P, King J, MacDonald J, McCullough C, Noggle S, Rasgorshek E, Schorn S, Skogerson L, Sullins D, Sullivan D, Sussman M, Weibel M.

J AOAC Int. 2010 Mar-Apr;93(2):638-49.

PMID:
20480912
12.

Cataplexy Emotional Trigger Questionnaire (CETQ)--a brief patient screen to identify cataplexy in patients with narcolepsy.

Moore WR, Silber MH, Decker PA, Heim-Penokie PC, Sikkink VK, Slocumb N, Richardson JW, Krahn LE.

J Clin Sleep Med. 2007 Feb 15;3(1):37-40.

PMID:
17557451
13.

Early prosthetic complications after unipolar hemiarthroplasty.

Weinrauch PC, Moore WR, Shooter DR, Wilkinson MP, Bonrath EM, Dedy NJ, McMeniman TJ, Jabur MK, Whitehouse SL, Crawford RW.

ANZ J Surg. 2006 Jun;76(6):432-5.

PMID:
16768762
14.

Maximizing discovery efficiency with a computationally driven fragment approach.

Moore WR Jr.

Curr Opin Drug Discov Devel. 2005 May;8(3):355-64. Review.

PMID:
15892251
15.

Characterizing the emotions that trigger cataplexy.

Krahn LE, Lymp JF, Moore WR, Slocumb N, Silber MH.

J Neuropsychiatry Clin Neurosci. 2005 Winter;17(1):45-50.

PMID:
15746482
16.

Obstructive sleep apnea-hypopnea syndrome.

Olson EJ, Moore WR, Morgenthaler TI, Gay PC, Staats BA.

Mayo Clin Proc. 2003 Dec;78(12):1545-52. Review.

PMID:
14661684
17.

Synthesis of 21,21-difluoro-3 beta-hydroxy-20-methylpregna-5,20-diene and 5,16,20-triene as potential inhibitors of steroid C17(20) lyase.

Weintraub PM, Holland AK, Gates CA, Moore WR, Resvick RJ, Bey P, Peet NP.

Bioorg Med Chem. 2003 Feb 6;11(3):427-31.

PMID:
12517438
18.

Synthetic bone graft substitutes.

Moore WR, Graves SE, Bain GI.

ANZ J Surg. 2001 Jun;71(6):354-61. Review.

PMID:
11409021
19.

Narcolepsy and obesity: remission of severe cataplexy with sibutramine.

Krahn LE, Moore WR, Altchuler SI.

Sleep Med. 2001 Jan;2(1):63-65.

PMID:
11152984
20.
21.

Neutrophil myeloperoxidase is a potent and selective inhibitor of mast cell tryptase.

Cregar L, Elrod KC, Putnam D, Moore WR.

Arch Biochem Biophys. 1999 Jun 1;366(1):125-30.

PMID:
10334872
22.

Inhibitors of tryptase for the treatment of mast cell-mediated diseases.

Rice KD, Tanaka RD, Katz BA, Numerof RP, Moore WR.

Curr Pharm Des. 1998 Oct;4(5):381-96. Review.

PMID:
10197050
23.

Design of potent selective zinc-mediated serine protease inhibitors.

Katz BA, Clark JM, Finer-Moore JS, Jenkins TE, Johnson CR, Ross MJ, Luong C, Moore WR, Stroud RM.

Nature. 1998 Feb 5;391(6667):608-12.

PMID:
9468142
24.

Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep.

Elrod KC, Moore WR, Abraham WM, Tanaka RD.

Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):375-81.

PMID:
9279212
25.

(-) mating type-specific mutants of Phycomyces defective in sex pheromone biosynthesis.

Sutter RP, Grandin AB, Dye BD, Moore WR.

Fungal Genet Biol. 1996 Dec;20(4):268-79.

PMID:
9045757
26.

Inhaled tryptase causes bronchoconstriction in sheep via histamine release.

Molinari JF, Scuri M, Moore WR, Clark J, Tanaka R, Abraham WM.

Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):649-53.

PMID:
8810600
27.

Role of tryptase in immediate cutaneous responses in allergic sheep.

Molinari JF, Moore WR, Clark J, Tanaka R, Butterfield JH, Abraham WM.

J Appl Physiol (1985). 1995 Dec;79(6):1966-70.

PMID:
8847261
28.

Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep.

Clark JM, Abraham WM, Fishman CE, Forteza R, Ahmed A, Cortes A, Warne RL, Moore WR, Tanaka RD.

Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2076-83.

PMID:
8520778
29.

Mast cell tryptase: a new target for therapeutic intervention in asthma.

Tanaka RD, Clark JM, Warne RL, Abraham WM, Moore WR.

Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):408-9. No abstract available.

30.

Purification of 2,3-oxidosqualene cyclase from rat liver.

Moore WR, Schatzman GL.

J Biol Chem. 1992 Nov 5;267(31):22003-6.

31.

N-(1-oxododecyl)-4 alpha,10-dimethyl-8-aza-trans-decal-3 beta-ol: a potent competitive inhibitor of 2,3-oxidosqualene cyclase.

Wannamaker MW, Waid PP, Van Sickle WA, McCarthy JR, Wilson PK, Schatzman GL, Moore WR.

J Med Chem. 1992 Sep 18;35(19):3581-3. No abstract available.

PMID:
1404239
32.

The purification and properties of cancer procoagulant from murine tumors.

Moore WR.

Biochem Biophys Res Commun. 1992 Apr 30;184(2):819-24.

PMID:
1575750
33.

Contrast cholangiography versus ultrasonographic measurement of the "extrahepatic" bile duct: a two-fold discrepancy revisited.

Davies RP, Downey PR, Moore WR, Jeans PL, Toouli J.

J Ultrasound Med. 1991 Dec;10(12):653-7.

PMID:
1766032
34.
35.
36.

Enzymatic synthesis of novel glutathione analogs.

Moore WR, Meister A.

Anal Biochem. 1987 Mar;161(2):487-93.

PMID:
3555155
37.

Caustic ingestions. Pathophysiology, diagnosis, and treatment.

Moore WR.

Clin Pediatr (Phila). 1986 Apr;25(4):192-6. Review.

PMID:
3512143
38.

Perceptions of terminal illness by family physicians and relatives.

Moore WR.

Omega (Westport). 1983-1984;14(4):369-76. No abstract available.

PMID:
11658465
39.

Peritoneal lavage in the treatment of acute pancreatic ascites.

Moore WR, Canton HH, Raines DR.

Am J Gastroenterol. 1978 Jan;69(1):88-91.

PMID:
645693
40.

Energy conservation program saves $89,000 dollars.

Moran AD, Moore WR.

Hosp Prog. 1977 May;58(5):50, 52, 56-7. No abstract available.

PMID:
852845
41.

Care of the dying.

Moore WR.

Br Med J. 1973 Feb 10;1(5849):353-4. No abstract available.

42.

Swaged gold eyelid weights.

Moore WR, Smith PL.

Dent Tech. 1972 Jul;25(7):151-2. No abstract available.

PMID:
4506426
43.

A first glance at terminal care.

Moore WR.

J R Coll Gen Pract. 1971 Jul;21(108):387-92. No abstract available.

44.

Pulmonary actinomycosis simulating cancer of the lung.

Moore WR, Scannell JG.

J Thorac Cardiovasc Surg. 1968 Feb;55(2):193-5. No abstract available.

PMID:
5635978
45.

A WORD ON SYMPATHY.

MOORE WR.

J Coll Gen Pract. 1965 Jan;9:103-5. No abstract available.

46.

Words of medicine.

MOORE WR.

Med World. 1957 Dec;87(6):549-50. No abstract available.

PMID:
13492850
47.

Inguinal endometriosis in bilateral hernia sacs associated with extensive pelvic endometriosis.

MOORE WR.

Harper Hosp Bull. 1957 Nov-Dec;15(6):242-5. No abstract available.

PMID:
13562731
48.

Theca cell tumor of the ovary; case report.

MOORE WR, WILLSON DD.

Harper Hosp Bull. 1951 Jan-Feb;9(1):7-10. No abstract available.

PMID:
14813601
49.

Beta-glucuronidase levels in placentas of normal and toxemic pregnancies.

COHEN ES, MOORE WR, SMITH BP.

Harper Hosp Bull. 1950 Nov-Dec;8(6):152-8. No abstract available.

PMID:
14802925
50.

Meconium peritonitis.

MAGUIRE CH, MOORE WR.

Surgery. 1950 Sep;28(3):568-73. No abstract available.

PMID:
14776665

Supplemental Content

Loading ...
Support Center